Ionis Pharmaceuticals, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
Ionis Pharmaceuticals, Inc. (IONS) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $3.60 million as of 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2017-05-09
- 2017-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $3.60M.
- 2016-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2017-03-31 | $3.60M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $0.00 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |